BioSpace News Archive

Cue Health (Nasdaq: HLTH), a healthcare technology company, announced today the peer-reviewed publication of an independent clinical study - the largest of its kind on asymptomatic people - finding that Cue’s molecular COVID-19 test provides comparable accuracy to centralized lab-based RT-PCR with the advantages of convenient use at the point-of-care or home settings and fast results in 20 minutes.

InsightRX – which provides cloud-based precision medicine software to optimize treatment decisions – today announced that results of several studies analyzing the use of its software for model-informed precision dosing (MIPD) will be presented at IDWeek 2023, October 11-15 in Boston.

Dimension Inx, a biomaterials platform company, today announced that CMFlex™, the first 3D-printed regenerative bone graft product with FDA approval, has been successfully used in its first clinical cases.

Today, Sanguina, Inc. (Sanguina), a leading biotech company, is pleased to announce the FDA clearance of AnemoCheck Home, the only FDA-cleared home hemoglobin test kit available in the United States.

Clarix Imaging, a medical technology company revolutionizing surgical oncology, announces $10 million in funding from kineo finance, a Swiss-headquartered investment firm.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, is thrilled to announce a US exclusive distribution partnership with Mercury Medical for non-government acute care facilities.

University of Maryland School of Medicine Dean Mark T. Gladwin, MD, and University of Maryland Medical Center President and CEO Bert W. O’Malley, MD, announced that Taofeek K. Owonikoko, MD, PhD, a distinguished physician-scientist with a global reputation in thoracic oncology, has been appointed Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced the presentation of encouraging pharmacodynamic data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumor cancers.

Biotricity, Inc., a Technology-as-a-Service company operating in the remote cardiac monitor sector of consumer healthcare, announced the filing of a patent application for its groundbreaking Biotres device.

Sosei Group Corporation (“Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD).